Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2Cell: CTCs and Adjuvant De-escalation in HER2+ Breast Cancer
NCT04993014Phase 2Recruiting
- Sponsor
- A.C.Camargo Cancer Center
- Start
- Mar 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in HER2-positive breast cancer, sponsored by A.C.Camargo Cancer Center. Started Mar 2021; status: recruiting.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04993014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993014.